| Zacks Company Profile for Champions Oncology, Inc. (CSBR : NSDQ) |
|
|
| |
| • Company Description |
| Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland.
Number of Employees: 210 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $8.81 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 26,334 shares |
| Shares Outstanding: 13.83 (millions) |
| Market Capitalization: $121.82 (millions) |
| Beta: 0.44 |
| 52 Week High: $11.99 |
| 52 Week Low: $3.60 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
19.14% |
14.67% |
| 12 Week |
10.54% |
-7.02% |
| Year To Date |
2.80% |
-3.73% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Ronnie Morris - Chief Executive Officer and Director
Joel Ackerman - Chairman of the Board of Directors and Director
David Miller - Chief Financial Officer
David Sidransky - Director
Robert Brainin - Director
|
|
Peer Information
Champions Oncology, Inc. (GSAC)
Champions Oncology, Inc. (CASI)
Champions Oncology, Inc. (ALCD.)
Champions Oncology, Inc. (OMNN)
Champions Oncology, Inc. (CGPI.)
Champions Oncology, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 15870P307
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: April
Last Reported Quarter: 01/01/25
Next Expected EPS Date: 07/17/25
|
|
Share - Related Items
Shares Outstanding: 13.83
Most Recent Split Date: 8.00 (0.08:1)
Beta: 0.44
Market Capitalization: $121.82 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/17/25 |
|
|
|
| |
